Skip to content

SOMA+PHARM News

Important Information

Dear Sir or Madam, in the last six months, there have been many positive business developments. We have repositioned ourselves and will inform you shortly.

More information

Investor event

On November 25, 2019, our very successful first event for investors and interested parties took place. The response of the attendees, from private persons to

More information

BioTempero

With the successful proof of principle tests at the University Hospital in Tübingen, we have taken the next step towards licensing BioTempero and are thus

More information

Management

The management of Somapharm AG is proud and pleased about the completion and dispatch of the new share certificates for our shareholders. Since the parliamentary

More information

CARDISIO

The fast and precise screening method for early detection of heart disease and prevention of a surprising heart attack. Complementing ALiSE, we are launching Cardisio,

More information

ALiSE

The management of Somapharm AG is very pleased to have been granted exclusive distribution rights in Europe, including Switzerland, for a new portable and miniaturized

More information

BARS

In cooperation with the company FISO Technologies Inc. from Canada, and supported by Innoswiss, a new sensor for intensive care measurement purposes is currently being

More information

The measurement catheter

The documents for the clinical tests were submitted to the Ethics Committee of the University Hospital in Tübingen towards the end of March. The approval

More information